Track Rocket Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Rocket Pharmaceuticals, Inc. RCKT · Stock Open Rocket Pharmaceuticals, Inc. in new tab

2.30 USD
EPS
-0.15
P/B
0.78
ROE
-5.04
Beta
0.49
Target Price
9.09 USD
Loading chart...
Key Metrics
Earnings dateMarch 1, 2027
EPS-0.15
Book Value2.93
Price to Book0.78
Debt/Equity16.85
% Insiders3.286%
Estimates
Forward P/E-1.44
Forward EPS-1.60
Target Mean Price9.09

DCF valuation

Model fair value for Rocket Pharmaceuticals, Inc. (RCKT)
Result
Sign in to run the valuation for RCKT.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
11 analysts · consensus Buy · mean target 9.09 USD (low 4.00, high 15.00) · as of 14 Nov 2026
Low 4.00
Mean 9.09
High 15.00
Price 2.30
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Rocket Pharmaceuticals, Inc. Logo Rocket Pharmaceuticals, Inc. Analysis (RCKT)

United States Health Care Official Website Stock

Is Rocket Pharmaceuticals, Inc. a good investment? Rocket Pharmaceuticals, Inc. (RCKT) is currently trading at 2.30 USD. Market analysts have a consensus price target of 9.09 USD. This suggests a potential upside from current levels.

Earnings Schedule: Rocket Pharmaceuticals, Inc. is expected to release its next earnings report on March 1, 2027. The market consensus estimate for Forward EPS is -1.60.

Investor FAQ

Does Rocket Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Rocket Pharmaceuticals, Inc.?

Rocket Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 1, 2027. The company currently has a trailing EPS of -0.15.

Company Profile

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Exchange Ticker
NMS (United States) RCKT
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Jan. 5, 2018 1:4
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion